About dabrafenib mesylate eq to dabrafenib
BRAF kinase inhibitor
Used for
- Treats certain BRAF V600 mutation-positive melanomas
- Treats certain BRAF V600 mutation-positive lung cancers
- Treats certain BRAF V600 mutation-positive thyroid cancers
- Used alone or with trametinib, depending on cancer type
Usual adult dose
Usually 150 mg by mouth twice daily; dose depends on cancer and combination treatment.
Usual dose in children
For selected cancers, usually 2.25 mg/kg twice daily, up to 150 mg twice daily; specialist dosing applies.
Common side effects
- Fever and chills
- Fatigue and headache
- Nausea, vomiting, or diarrhea
- Rash and other skin problems
Important warnings
- Can cause serious fever, dehydration, or kidney problems
- May cause new skin cancers or other malignancies
- Can cause bleeding, heart problems, or eye inflammation
- Requires confirmation of a relevant BRAF mutation
Pregnancy
May harm an unborn baby. Effective contraception is needed during treatment and for two weeks afterward.
Breastfeeding
Breastfeeding is not recommended during treatment and for two weeks after the last dose.
Interactions
- Hormonal contraceptives may become less effective
- Some medicines affect dabrafenib levels, including rifampin and ketoconazole
- May reduce levels of warfarin and other medicines
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.